Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C37450
http://purl.obolibrary.org/obo/NCIT_C37450
|
|---|---|
| Preferred Name | NA17-A Antigen |
| Definitions |
A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues. |
|---|---|
| prefLabel | NA17-A Antigen
|
| label | NA17-A Antigen
|
| PDQ_Closed_Trial_Search_ID | 38647
|
| code | C37450
|
| prefixIRI | NCIT:C37450
|
| in_subset | |
| Preferred_Name | NA17-A Antigen
|
| Maps_To | NA17-A Antigen
|
| NCI_Drug_Dictionary_ID | 38647
|
| Legacy Concept Name | NA17-A_Antigen
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38647
|
| Semantic_Type | Immunologic Factor
|
| UMLS_CUI | C1134655
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |